Frequency: Quarterly E- ISSN: 2278-4101 P- ISSN: IBI Factor: 4.09 Abstracted/ Indexed in: Ulrich's International Periodical Directory, Google Scholar, SCIRUS, Genamics Journal Seek, PSOAR, getCITED, InfoBase Index, EBSCO Information Services
Quarterly published in print and online "Inventi Rapid: Pharmacokinetics & Pharmacodynamics" publishes high quality unpublished as well as high impact pre-published research and reviews catering to the needs of researchers and professionals. This journal focuses on all areas of pharmacokinetics and pharmacodynamics of drug substances and products including drug absorption, distribution, metabolism and excretion, and application of pharmacokinetics principles for effective management of drugs. Articles from the areas such as drug action, clinical pharmacokinetics, drug metabolites, dosage form evaluation in animals and humans, bioavailabilty studies, scaling from animals to humans, and in vitro and in vivo correlations are also welcome.
In the present study, a non-invasive, methyl nicotinate (MN) induced erythema model using Laser Doppler Flowmeter was standardized and successfully validated to perform the effect-time study on healthy human male volunteers after oral administration of 400 mg tablets of dexibuprofen. MN was applied on the volar region of forearm (20 �µl) for 6 min to produce a visible vasodilation i.e. increase in mean cutaneous blood flow. It remained constant for 10 minutes after which it declined gradually. The effect of dexibuprofen was determined from the response of LDF to the MN challenge by calculating the percent inhibition of MN induced inflammation by dexibuprofen for each time point. It was observed that dexibuprofen inhibited the inflammation by approximately 35 % in the 0.5 h of dosing of dexibuprofen formulation. The observed mean maximum inhibition (Emax) was 93.64�±4.57 % and 95.22�±3.61 %; and the corresponding mean time to maximum effect was found to be 2.08�±0.36 h and 2.17�±0.33 h for the test and comparator formulations, respectively. Therefore, It is suggested that this non-invasive technique can be adopted in various fields of research, where, efficacy of NSAIDs to be quantified in terms of their effect on a cutaneous challenge by nicotinic ester....
A novel transdermal patch of Metformin was prepared for the sustained release of drug. The transdermal patch of metformin was prepared by solvent casting technique. Bioavailability of metformin is 50-60% and half life is 6.2 hr. HPMC-E50LV, HPMC-E100M and ethyl cellulose was used for matrixing agent and PEG-400 is used as plasticizer. DMSO (dimethyl sulphoxide) is used as penetration enhancer. Methanol and Dichloromethane is use as solvent. Patch are evaluated by thickness, tensile strength, folding endurance, drug content uniformity The data of in-vitro dissolution , % moisture content, % moisture loss, and in vitro release. This patch is use for the treatment of type-II diabetes (diabetes mellitus) it decreases the LDL level and used for over fat persons. The aim of this article for sustained release of drug and main advantages are avoid first pass hepatic metabolism, avoid the risk of intravenous therapy, and increase bioavailability....
Steroidal esters of 17-oximino-5 androsten-3�Ÿ-ol were synthesized from dehydroandrosterone acetate. These compounds were tested for their antiproliferating activity and 5a-Reductase inhibitory activity in comparison to finasteride. Decreased androgen levels have been found in serum of animals treated with newly synthesized compounds. These compounds have shown better cytotoxicity as comparison to the clinically used drug finasteride. Therefore these compounds can be useful in the treatment of androgen dependent disorders of prostate alone or by synergistic effect they can decrease the size of prostate due to their antiproliferating activity. The compound TRB-263 was synthesized from the diosgenin involving marker degradation, oximation, Beckmann rearrangement, acid hydrolysis, oximation and esterification.All the phaemacokinetics parameters were determined using male wistar rats by the RP-HPLC.Male wistar rats were selected for the determination of all the pharmacokinetic parameters of TRB-263 by the oral administration of both finasteride and TRB-263, 0.4 ml of blood samples were collected from retro orbital plexus at 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16 in heparinised tubes and after i.v. injection of finasteride and TRB-263, 0.4 ml of blood samples were collected from retro orbital plexus of at 0, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 16....
Rivastigmine is an effective reversible acetyl cholinesterase inhibitor used for the treatment of mild to moderate dementia. It was approved by US Food and drug administration for Alzheimer’s disease dementia. In this review, the advances of Alzheimer’s disease dementia and pharmacokinetics and pharmacodynamic properties, efficacy and tolerability profile new clinical approaches, adverse events and serious adverse events, drug interaction and pharmacoeconomics of rivastigmine were concluded and summarised. In the clinical trials conducted on rivastigmine, stated that it is effective against cognitive functions, global function such as memory, language, attention and problem solving ability and behaviour in patient with mild to moderate Alzheimer’s disease dementia for upto 52 weeks. It is completely. In comparison with parent drug Rivastigmine has at least 10 fold lower activity against AChE. Occurred adverse events are mild and affect the gastrointestinal tract. In clinical trials rivastigmine have not shown clinically significant drug interactions thus drug interactions were not reported. Continuous treatments with rivastigmine for upto 52 weeks may reduce the patient caring with Alzheimer’s disease dementia. Rivastigmine has been shown to determination or uphold patient’s enactment in major 3 fields such as cognitive functions, global functions (Alzheimer’s disease dementia) and behaviour. Various clinical trials results show the efficacy and tolerability of rivastigmine with most protuberant adverse effects being gastrointestinal tract irritation....
One of the most quick and comprehensive way of determining the in-vivo pharmacokinetic profile is gamma scintigraphic study of labelled bio-medicals, materials and pharmaceuticals with radiation emitting isotopes. The formation of chemical bond between isotope and drug using a chelating agent gives a formulation called as radiopharmaceutical. Binding of two components is radiolabeling. The tagging of radionuclide helps in tracing the bioavailability and bio-distribution study of radiolabelled compound to the target organ. The method adopted in radiolabeling evaluates radiochemical purity by quality control parameter like ITLC which determines the labelling efficiency. Therefore, in nuclear medicine it can be said that higher the labelling efficiency, better the in-vivo evaluation of pharmacokinetic profile of drug. The administration of dosage form tagged with radionuclide can provide vital information about the in-vivo behaviour, extent, rate and site, mode of drug release and morphology of the target organ in animal or human being within the limits of ethical norms....
Loading....